Showing 1281-1290 of 1779 results for "".
Expanding the Field: A New Botulinum Neurotoxin A Enters The US Arena
https://practicaldermatology.com/topics/general-topics/PD0609_07-php/22816/A cosmetic dermatologist with experience using Dysport describes how clinicians may approach the new agent in practice.Is Bone Mineral Density Testing Indicated with Long-Term IM Triamcinolone Acetonide Therapy?
https://practicaldermatology.com/topics/general-topics/PD1208_05-php/22603/Prospective data are lacking, but early findings suggest little if any risk of density-loss among patients on long-term therapy.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muA Guide to Building Lifelong Patient Loyalty
https://practicaldermatology.com/issues/october-2025/a-guide-to-building-lifelong-patient-loyalty/39758/Interest in medical aesthetic treatments continues to grow and signs indicate that demand will remain strong. Today’s patients are more informed and educated than ever and are seeking personalized, high-quality experiences.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuPreparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Dermatology Recruitment in the Age of Private Equity
https://practicaldermatology.com/issues/september-2025/dermatology-recruitment-in-the-age-of-private-equity/37638/A recruiting executive offers a balanced view from the fieldWhat (More) Do You Want From Me? Reflections on Mentorship, Dermatology, and Moving Forward
https://practicaldermatology.com/issues/september-2025/what-more-do-you-want-from-me-reflections-on-mentorship-dermatology-and-moving-forward/37625/Professionally and personally, it’s hard to avoid the “what if” and “if only” scenarios. But when those thoughts outweigh the pride in where we’ve landed or who we’ve become, maybe it’s time to pause and appreciate the labor and sacrifices that got us here.Busy by Design Plans: How to Use Downtime to Drive Revenue and Make Uptime Smoother for Your Team
https://practicaldermatology.com/issues/september-2025/busy-by-design-plans-how-to-use-downtime-to-drive-revenue-and-make-uptime-smoother-for-your-team/37641/In today’s fast-paced dermatology industry, treatments can sometimes feel more transactional than transformational.Structure: The Backbone of a Practice Transaction
https://practicaldermatology.com/topics/practice-management/structure-the-backbone-of-a-practice-transaction/23961/